Source – Sanofi
Paris, July 28, 2023. Sanofi announces its strategic move to acquire Qunol, a renowned and leading brand in health and wellness based in the United States. This acquisition is part of Sanofi’s plan to bolster its Consumer Healthcare’s (CHC) Vitamin, Mineral, and Supplements (VMS) category, which happens to be one of the most extensive and rapidly growing consumer health segments in the US The primary focus of this expansion will be on the active ‘healthy aging’ segment.
“The acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing ‘healthy aging’ segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our U.S. presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”
– Executive Vice President, Consumer Healthcare, Sanofi
By incorporating Qunol’s CoQ10 in heart health and Turmeric in joint health, Sanofi’s Consumer Healthcare division gains access to a highly trusted and profitable brand experiencing double-digit growth. The acquisition aligns well with the increasing consumer demand for products addressing chronic health conditions. With a commitment to providing science-backed products, Qunol has built a strong market position and enjoys significant brand equity among both consumers and customers, leading to a high level of consumer loyalty above the industry average.
Sanofi recognizes the potential in Qunol’s CoQ10 and Turmeric offerings and intends to leverage its Consumer Healthcare resources to explore expansion opportunities into other chronic health conditions while also considering global market expansion beyond the US
“Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awareness for our products with our consumers and customers. With Sanofi, we have the opportunity to further grow in the US and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”
– CEO, Quten Research Institute, LLC
The agreement to acquire Qunol is subject to customary closing conditions, including obtaining necessary regulatory approvals. The anticipated timeline for completing the acquisition is during the third quarter of 2023. This move demonstrates Sanofi’s dedication to pursuing growth opportunities and creating value within its consumer healthcare business.
